Return to MD Anderson Cancer Center

Return to Department of Thoracic and Cardiovascular Surgery

What's New
Faculty & Staff
  Jack Roth, M.D.
    Curriculum Vitae
    Journal Articles
Education
Specific Diseases
Videos
Research
F.A.Q.
Glossary of Terms
Web Links
Thoracic Center
Contact Information

 

  

Bibliography- Jack A. Roth, M.D.

Published and accepted articles in refereed journals:

  1. Roth, J.A., Greenfield, A.J., Kiahara, S., and Wagner, H.N., Jr. Total and regional cerebral blood flow in unanesthetized dogs. Am. J. Physiol., 219:96-101, 1970.
  2. Roth, J.A., and Rutherford, R.B. Regional blood flow effects of G-suit application during hemorrhagic shock. Surg. Gynecol. Obstet., 133:637-643, 1971.
  3. Roth, J.A., ter Haar, A.M., Krajewski, C.A., and Williams, G.M. Nucleic acid synthesis in allograft endothelium. Surg. Forum, 22:264-266, 1971.
  4. Williams, G.M., Krajewski, C.A., Dagher, F.J., ter Haar, A.M., Roth, J.A., and Santos, G.W. Host repopulation of endothelium. Transplant Proc., 3:869-872, 1971.
  5. Boddie, W.A. Jr., Holmes, E.C., and Roth, J.A. Inhibition of human leukocyte migration in agarose by KCI extracts of lung cancer. Surg. Forum, 25:109-110, 1974.
  6. Roth, J.A. Patients with hyperbilirubinemia and hyperamylasemia: Is the pancreatitis or biliary lithiasis Am. J. Surg., 40:321-325, 1974.
  7. Roth, J.A., Slocum, H.K., Pellegrino, M.A., Holmes, E.C., and Reisfeld, R.A. Purification of a soluble human melanoma-associated antigens. Cancer Res., 36:2360-2364, 1974.
  8. Roth, J.A., Golub, S.H., Grimm, E.A., Eilber, F.R., and Morton, D.L. Effect of surgery on in vitro lymphocyte function. Surg. Forum, 25:102-104, 1974.
  9. Boddie, W.A. Jr., Holmes, E.C., Roth, J.A., and Morton, D.L. Inhibition of human leukocyte migration in agarose by KCI extracts carcinoma of the lung. Int. J. Cancer, 15:823-829, 1975.
  10. Holmes, E.C., Roth, J.A., and Morton, D.L. Delayed cutaneous hypersensitivity reactions to melanoma antigen. Surgery, 78:160-164, 1975.
  11. Roth, J.A., Eilber, F.R., Bennett, L.R., and Morton, D.L. Usefulness of pre-operative evaluation of melanoma patients. Arch. Surg., 110:1211-1212, 1975.
  12. Roth, J.A., Silverstein, M.J., Morton, D.L., and Gupta, R.K. Restoration of immunocompetency by lymphocytes transfusion. J. Surg. Oncol., 7:63-66, 1975.
  13. Roth, J.A., Holmes, E.C., Boddie, A.W. Jr., and Morton, D.L. Lymphocyte responses of lung cancer patients to tumor-associated antigen measured by leucine incorporation. J. Thorac. Cardiovasc. Surg., 70:613-618, 1975.
  14. Roth, J.A., Eilber, F.R., Nizze, J.A.N., and Morton, D.L. Lack of correlation between skin reactivity to dinitrochlorobenzene and croton oil in patients with cancer. N. Engl. J. Med., 293:388-389, 1975.
  15. Roth, J.A., Golub, S.H., Holmes, E.C., and Morton, D.L. Effect of Bacillus Calmette-guerin immunotherapy on tumor antigen-induced lymphocyte-stimulated protein synthesis in melanoma patients. Surgery, 78:66-75, 1975.
  16. Waldman, S.R., Roth, J.A., Kern, D.H., and Pilch, Y.H. Effects on cancer patients of leukapheresis with the continuous-flow blood cell separator. II. Immunologic parameters in vitro. J. Lab. Clin. Med., 86:950-961, 1975.
  17. Waldman, S.R., Roth, J.A., Silverstein, M., Veltman, L.L., and Pilch, Y.H. Effects on cancer patients of leukapheresis with the continuous-flow blood cell separator. I. Hematologic and immunologic parameters in vivo. J. Lab. Clin. Med., 86:938-949, 1975.
  18. Williams, G.M., ter Haar, A., Krajewski, C., Parks, L.C., and Roth, J.A. Rejection and repair of endothelium in major vessel transplants. Surgery, 78:694-706, 1975.
  19. Winters, W.D., Boddie, W.A. Jr., and Roth, J.A. Biological activation of virus-like particles from chemically-induced guinea pig sarcomas. Proc. Soc. Exp. Biol. Med., 149:714-722, 1975.
  20. Golub, S.H., Roth, J.A., Forsythe, A., and Morton, D.L. In vitro monitoring of cellular function during BCG immunotherapy. Biblio Haematol., 43:270-273, 1975.
  21. Chee, D.L., Boddie, A.W. Jr., Roth, J.A., Holmes, E.C., and Morton, D.L. Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. Cancer Res., 36:1503-1509, 1976.
  22. Grimm, E., Silver, H.K.B., Roth, J.A., Chee, D.O., Gupta, R.K., and Morton, D.L. Detection of tumor-associated antigen in human melanoma cell line supernatants. Int. J. Cancer, 17:559-564, 1976.
  23. Roth, J.A., Holmes, E.C., Reisfeld, R.A., Slocum, H.K., and Morton, D.L. Isolation of a soluble tumor-associated antigen from human melanoma. Cancer, 37:104-110, 1976.
  24. Roth, J.A., Grimm, E.A., and Morton, D.L. A rapid assay for stimulation of human lymphocytes by tumor-associated antigens. Cancer Res., 36:3001-3010, 1976.
  25. Roth, J.A., Silverstein, M.J., and Morton, D.L. Metastatic potential of metastases. Surgery, 79:669-673, 1976.
  26. Roth, J.A., Golub, S.H., Grimm, E.A., Eilber, F.R., and Morton, D.L. Effects of operation on immune response in cancer patients: sequential evaluation of in vitro lymphocyte function. Surgery, 79 :46-51, 1976.
  27. Roth, J.A., Feinberg, M., and McAvoy, J.M. Carcinoma arising in the wall of a breast cyst during pregnancy: case report and review of the literature. Ann. Surg., 185:247-250, 1977.
  28. McAvoy, J.M., Roth, J.A., Rees, W.V., Orr, F., and Dainko, E.A. Role of ultrasonography in the primary diagnosis of cholelithiasis. Am. J. Surg., 136:309-312, 1978.
  29. McAvoy, J.M., Fee, H.J., Roth, J.A., and Dainko, E.A. Primary liposarcoma of the omentum. Arch. Surg., 113:870-872, 1978.
  30. Roth, J.A., Eilber, F.R., and Morton, D.L. Effect of adriamycin and high dose methotrexate chemotherapy on in vivo and in vitro cell-mediated immunity in cancer patients. Cancer, 41:814-819, 1978.
  31. Roth, J.A., Zuckerbraun, L., and Cohn, D. Lymphosarcoma presenting as a parotid mass. Ear Nose Throat J, 57:434-438, 1978.
  32. Roth, J.A., Morton, D.L., and Holmes, E.C. Rejection of DNCB-conjugated syngeneic tumor cells by DNCB-sensitized guinea pigs. J. Surg. Res., 25:1-7, 1978.
  33. Ramming, K.P., Roth, J.A., and Mulder, D.G. Surgical management of extensive tracheal lesions. Am. J. Surg., 138:80-88, 1979.
  34. Roth, J.A., Cukingnan, R.A., and Scott, C.R. Use of activated coagulation time to monitor heparin during cardiac surgery. Ann. Thorac. Surg., 28:69-72, 1979.
  35. Roth, J.A., Cukingnan, R.A., Brown, B.G., Gocka, E., and Carey, S. Factors influencing patency of saphenous vein grafts. Ann. Thorac. Surg., 28:176-183, 1979.
  36. Roth, J.A., and Morton, D.L. Studies of lymphocyte stimulation to tumor-associated antigen: I. uptake of lymphocyte protein and nucleic acid precursors in response to autologous and allogeneic tumor-associated antigen solubilized from human tumors. Cancer Immunol. Immunother., 7:19-23, 1979.
  37. Roth, J.A., Chee, D.O., Gupta, R.K., and Morton, D.L. Studies of lymphocyte stimulation to tumor-associated antigen: II. comparison of extracts from fresh human tumors with tissue culture cell lines. Cancer Immunol. Immunother., 7:25-29, 1979.
  38. Roth, J.A., Golub, S.H., Cukingnan, R.A., Brazier, J., and Morton, D.L. Cell-mediated immunity is depressed following cardiopulmonary bypass. Ann. Thorac. Surg., 31:350-356, 1981.
  39. Roth, J.A. Humoral immune responses to human primary and metastatic sarcomas detected by an enzyme-linked immunoabsorbent solid-phase assay. Surg. Forum, 32:454-456, 1981.
  40. Roth, J.A., and Wesley, R. Human tumor-associated antigens detected by serologic techniques: analysis of autologous humoral immune responses to primary and metastatic human sarcomas by an enzyme-linked immunoabsorbent solid-phase assay (ELISA). Cancer Res., 42:3978-3986, 1982.
  41. Roth, J.A., Grimm, E.A., Gupta, R.K., and Ames, R.S. Immunoregulatory factors derived from human tumors. I. Immunological and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro. J. Immunol., 128:1955-1962, 1982.
  42. Roth, J.A., and Osborne, B.A. Detection of an immunosuppressive immunoregulatory factor (IRF) in the sera of sarcoma patients by enzyme-linked immunoassay (ELISA) and correlation with clinical course. Surg Forum, 33:429-431, 1982.
  43. Schwartz, J., Roth, J.A., and Carpentier, B. Effect of human lung carcinoma extract as an immunosuppressant of allografts in rats. Afr. J. Clin. Exp. Immunol., 3:191-197, 1982.
  44. Grimm, E.A., Robb, R.J., Roth, J.A., Neckers, L.M., Lachman, L.B., Wilson, D.J., and Rosenberg, S.A. Lymphokine-activated killer cell (LAK) phenomenon: III. evidence that IL-2 is sufficient for direct activation of PBL into LAK. J. Exp. Med., 158:1356-1361, 1983.
  45. Putnam, J.B., Jr., Roth, J.A., Wesley, M.N., Johnston, M.R., and Rosenberg, S.A. Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors. Ann. Thorac. Surg., 36:516-523, 1983.
  46. Roth, J.A., Osborne, B.A., and Ames, R.S. Immunoregulatory factors derived from human tumors. II: partial purification and further immunobiochemical characterization of a human sarcoma-derived immunosuppressive factor expressing HLA-DR and immunoglobulin-related determinants. J. Immunol., 130:303-308, 1983.
  47. Roth, J.A. Detection of a suppressive immunoregulatory factor (IRF) in the sera of sarcoma patients by enzyme-linked immunoassay (ELISA) and correlation with clinical course. J. Surg. Oncol., 23:273-281, 1983.
  48. Roth, J.A., Davidson, D.D., Ames, R.S., and Schneider, P.D. Tumor stasis factor (TSF): a possible mechanism for the regulation of tumor cell proliferation. J. Surg. Res., 35:298-309, 1983.
  49. Roth, J.A., Grimm, E.A., Osborne, B.A., Putnam, J.B. Jr., Davidson, D.D., and Ames, R.S. Suppressive immunoregulatory factors produced by tumors. Lymphokine Res., 2:67-73, 1983.
  50. Thistlewaithe, P., Davidson, D.D., Fidler, I.J., and Roth, J.A. Syngeneic humoral immune responses to tumor-associated antigens expressed by K-1735 UV-induced melanoma and its metastases. Cancer Immunol. Immunother., 15:11-16, 1983.
  51. Funkhouser, W.K., Neckers, L.M., Ames, R.S., and Roth, J.A. Human tumor cell growth inhibition by a tumor-derived glycoprotein. Surg. Forum, 35:394-396, 1984.
  52. Keller, S.M., Papazaglou, S., McKeever, P., Baker, A., and Roth, J.A. Late occurrence of malignancy in a ganglioneuroma 19 years following radiation therapy to a neuroblastoma. J. Surg. Oncol., 25:227-231, 1984.
  53. Pass, H.I., Potter, D.A., Macher, A.M., Reichert, C., Shelhammer, J.H., Masur, H., Ognibene, F., Gelmann, E., Lane, H.C., Fauci, A., and Roth, J.A. Thoracic manifestations of the acquired immune deficiency syndrome. J. Thorac. Cardiovasc. Surg., 88:654-658, 1984.
  54. Potter, D.A., Strott, C.A., Javadpour, N., and Roth, J.A. Prolonged survival following six pulmonary resections for metastatic adrenal cortical carcinoma: a case report. J. Surg. Oncol., 25:273-277, 1984.
  55. Putnam, J.B., Jr., Roth, J.A., Wesley, M.N., Johnston, M.R., and Rosenberg, S.A. Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. J. Thorac. Cardiovasc. Surg., 87:260-267, 1984.
  56. Roth, J.A., Sugarbaker, P.H., and Baker, A.R. Radical forequarter amputation with chest wall resection. Ann. Thorac. Surg., 37:423-427, 1984.
  57. Roth, J.A., Restrepo, C., Scuderi, P., Baldwin, R.W., Reichert, C.M., and Hosoi, S. Analysis of antigenic expression by primary and autologous metastatic human sarcomas using murine monoclonal antibodies. Cancer Res., 44:5320-5325, 1984.
  58. Roth, J.A., Scuderi, P., Westin, E., and Gallo, R.C. A novel approach to production of antitumor monoclonal antibodies: antibody to a cell surface glycoprotein associated with transformation by a human oncogene. Surgery, 96:264-272, 1984.
  59. Brown, B.G., Cukingnan, R.A., Goede, L.V., Wong, M., Fee, H.J., Roth, J.A., and Carey, J.S. Improved graft patency in patients treated with platelet-inhibiting therapy following coronary bypass. Circulation, 72:138-146, 1985.
  60. Chang, A.E., Lotze, M.T., Ames, R.S., Roth, J.A., and Rosenberg, S.A. A large scale method of separating multiple lymphokines secreted by the murine EL-4 thymoma. Immunopharmacology, 7:17-31, 1985.
  61. Davidson, D.D., Carney, D.N., Putnam, J.B. Jr., Sugarbaker, P.H., and Roth, J.A. Suppression of murine immunologic functions by fresh and cultured human tumor extracts. J. Surg. Res., 38:289-297, 1985.
  62. Glenn, J., Kinsella, T., Glatstein, E., Tepper, J., Baker, A., Sugarbaker, P., Sindelar, W., Roth, J.A., Brennan, M., Costa, J., Seipp, C., Wesley, R., Young, R.C., and Rosenberg, S.A. A randomized, prospective study of chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk. Cancer, 55:1206-1214, 1985.
  63. Inculet, R.I., Keller, S.M., Dwyer, A., and Roth, J.A. Evaluation of noninvasive tests for the preoperative staging of carcinoma of the esophagus: a prospective study. Ann. Thorac. Surg., 40:561-565, 1985.
  64. Lanza, L.A., Ames, R.S., Byers, V., Lee, H., Scannon, P., and Roth, J.A. Immunotoxin-mediated cytotoxity of human oncogene-transformed tumor cells. Surg. Forum, 35:381-383, 1985.
  65. Leong, S.P., Noguchi, P.D., Cunningham, R.E., Ames, R.S., Speiss, P.J., Takami, T., and Roth, J.A. Expression of a murine B16 melanoma-associated antigen analyzed by flow cytometry. J. Surg. Res., 38:383-390, 1985.
  66. Pass, H.I., Dwyer, A., Makuch, R., and Roth, J.A. Detection of pulmonary metastases in patients with osteogenic and soft-tissue sarcomas: the superiority of CT scans compared with conventional linear tomograms using dynamic analysis. J. Clin. Oncol., 3:1261-1265, 1985.
  67. Potter, D., Pass, H.I., Brower, S., Macher, A., Browne, M., Thaler, M., Cotton, D., Hawthorn, J., Wesley, R., Longo, D., Pizzo, P., and Roth, J.A. Prospective randomized study of open lung biopsy versus empirical antibiotic therapy for acute pneumonitis in non-neutropenic cancer patients. Ann. Thorac. Surg., 40:422-428, 1985.
  68. Putnam, J.B., Jr., and Roth, J.A. Identification and characterization of a tumor-derived immunosuppressive glycoprotein from murine melanoma K-1735. Cancer Immunol. Immunother., 19:90-100, 1985.
  69. Roth, J.A., Putnam, J.B. Jr., Wesley, M.N., and Rosenberg, S.A. Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Cancer, 55:1361-1366, 1985.
  70. Scuderi, P., Westin, E., Clagett, J., Ames, R., Gallo, R., Blick, M., and Roth, J.A. Detection of a surface antigen on NIH 3T3 cells transfected with a human leukemia oncogene. Med. Oncol. Tumor Pharmacother., 2:233-242, 1985.
  71. Edington, H., Salwitz, J., Longo, D.L., Roth, J.A., and Pass, H. Thymic hyperplasia masquerading as recurrent Hodgkin s Disease: Case report and review of the literature. J. Surg. Oncol., 33:120-123, 1986.
  72. Funkhouser, W.K., Neckers, L.M., Ames, R.S., Carney, D.N., and Roth, J.A. Inhibition of DNA synthesis by a small-cell lung carcinoma-derived protein. J. Natl. Cancer Inst., 77:925-932, 1986.
  73. Grimm, E.A., Jacobs, S.K., Lanza, L.A., Melin, G., Roth, J.A., and Wilson, D.J. Interleukin-2-activated cytotoxic lymphocytes in cancer therapy. Symposium on Fundamental Cancer Research, 38:209-219, 1986.
  74. Lanza, L.A., Wilson, D.J., Ikyejiri, B., Roth, J.A., and Grimm, E.A. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine activated killer cells (LAK) and natural killer cells. J. Immunol., 137:2716-2720, 1986.
  75. Lanza, L.A., Ames, R.S., Lee, H., Byers, V., Scannon, P., Trahan, E.E., and Roth, J.A. Immunotoxin to the gp74 c-Ha-ras-linked tumor antigen: serum clearance and efficacy against established metastases in a murine model. Surg. Forum, 37:413-415, 1986.
  76. McCormick, K.A., Carelli, R.M., Wesley, M., Roth, J.A., and Altizer, G. The effects of withdrawal methods on arterial cannula dysfunction. Mil. Med., 151:205-210, 1986.
  77. Pass, H.I., Potter, D., Shelhammer, J., Macher, A., Ognibene, F., Longo, D., Gelmann, E., Masur, H., and Roth, J.A. Indications for and diagnostic efficacy of open-lung biopsy in the patient with acquired immunodeficiency syndrome (AIDS). Ann. Thorac. Surg., 41:307-312, 1986.
  78. Rizzoni, W.E., Pass, H.I., Wesley, M.N., Rosenberg, S.A., and Roth, J.A. Resection of recurrent pulmonary metastases in patients with adult soft tissue sarcomas. Arch. Surg., 121:1248-1252, 1986.
  79. Roth, J.A., Pass, H.I., Wesley, M.N., White, D., Putnam, J.B., and Seipp, C. Comparison of median sternotomy and thoracotomy for resection of pulmonary metastases in patients with adult soft-tissue sarcomas. Ann. Thorac. Surg., 42:134-138, 1986.
  80. Roth, J.A., Ames, R.S., Restrepo, C., and Scuderi, P. Monoclonal antibody 45-2D9 recognizes a cell surface glycoprotein on a human c-Ha-ras transformed cell line (45-342) and a shared epitope on human tumors. J. Immunol., 137:2385-2389, 1986.
  81. Roth, J.A., Ames, R.S., Byers, V., Lee, H.M., and Scannon, P.J. Monoclonal antibody 45-2D9 conjugated to the A chain of ricin is specifically toxic to c-Ha-ras transfected NIH 3T3 cells expressing GP74. J. Immunol., 136:2305-2310, 1986.
  82. Udelsman, R., Roth, J.A., Lees, D., Jelenich, S.E., and Pass, H.I. Endobronchial metastases from soft tissue sarcoma. J. Surg. Oncol., 32:145-149, 1986.
  83. Lanza, L.A., Miser, J.S., Pass, H.I., and Roth, J.A. The role of resection in the treatment of pulmonary metastases from Ewing s sarcoma. J. Thorac. Cardiovasc. Surg., 94:181-187, 1987.
  84. Leong, S.P., Noguchi, P.D., Cunningham, R.E., Takami, T., and Roth, J.A. Heterogeneous expression of a murine B16 melanoma-associated antigen correlates with cell cycle. Cancer Immunol. Immunother., 24:106-112, 1987.
  85. Pass, H.I., Sindelar, W.F., Kinsella, T.J., Deluca, A.M., Barnes, M., Kurtzman, S., Hoekstra, H., Tochner, Z., Roth, J.A., and Glatstein, E. Delivery of intraoperative radiation therapy (IORT) after pneumonectomy: Experimental observations and early clinical results. Ann Thorac Surg, 44:14-20, 1987.
  86. Lefor, A.T., Merino, M.M., Steinberg, S.M., Dwyer, A., Roth, J.A., Flanagan, M., and Pass, H.I. Computerized tomographic prediction of extraluminal spread and prognostic implications of lesion width in esophageal carcinoma. Cancer, 62:1287-1292, 1988.
  87. Ogninbene, F.P., Pass, H.I., Roth, J.A., Shelhamer, J.H., and Milne, E.N.C. Role of imaging and interventional techniques in the diagnosis of respiratory disease in the immunocompromised host. J. Thorac. Imaging, 3:1-20, 1988.
  88. Pogrebniak, H.W., Stovroff, M., Roth, J.A., and Pass, H.I. Resection of pulmonary metastases from malignant melanoma: Results of a 16-year experience. Ann. Thorac. Surg., 46:20-23, 1988.
  89. Roth, J.A., Ames, R.S., Fry, K., Lee, H.M., and Scannon, P.J. Mediation of reduction of spontaneous and experimental pulmonary metastases by ricin A-chain immunotoxin 45-2D9-RTA with potentiation by systemic monensin in mice. Cancer Res., 48:3496-3501, 1988.
  90. Roth, J.A. Prognostic indicators for soft tissue sarcoma patients with pulmonary metastases. Dev. Oncol., 55:191-196, 1988.
  91. Roth, J.A., Pass, H.I., Flanagan, M.M., Graeber, G.M., Rosenberg, J.C., and Steinberg, S. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J. Thorac. Cardiovasc. Surg., 96:242-248, 1988.
  92. Yang, S.C., Owen-Schaub, L., Grimm, E.A., and Roth, J.A. Enhancement of lymphokine-activated killer activity with interleukin-2, tumor necrosis factor-?, and OKT3 against primary lung cancer targets. Surg. Forum, 39:454-456, 1988.
  93. Ames, R.S., North, S.M., Fry, K.D., Tainsky, M.A., Nicolson, G.L., and Roth, J.A. Analysis of expression of cell surface antigen MR 74,000 phosphoglycoprotein in normal, oncogene-transformed, and neoplastic rat cell lines. Cancer Res., 49:2312-2319, 1989.
  94. Jablons, D., Steinberg, S.M., Roth, J.A., Pittaluga, S., Rosenberg, S.A., and Pass, H.I. Metastasectomy for soft tissue sarcoma. further evidence for efficacy and prognostic indicators. J. Thorac. Cardiovasc. Surg., 97:695-705, 1989.
  95. Roth, J.A., Thomsen, S., Fry, K.D., Scannon, P., and Chang, C. Analysis of GP74 expression by transformed rat fibroblasts from experimental pulmonary metastases following specific ricin A-chain immunotoxin therapy. Cancer Res., 49:5708-5712, 1989.
  96. Schneider, P.M., Hung, M.C., Chiocca, S.M., Manning, J., Zhao, X.Y., Fang, K., and Roth, J.A. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res., 49:4968-4971, 1989.
  97. Wahi, R., McMurtrey, M., DeCaro, L.F., Mountain, C.F., Ali, M.K., Smith, T.L., and Roth, J.A. Determinants of perioperative morbidity and mortality after pneumonectomy. Ann. Thorac. Surg., 48:33-37, 1989.
  98. Yang, S.C., Owen-Schaub, L., Grimm, E.A., and Roth, J.A. Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-a against primary lung cancer targets. Cancer Immunol. Immunother., 29:193-198, 1989.
  99. Yang, S.C., Fry, K.D., Grimm, E.A., and Roth, J.A. Reduction of pulmonary metastases following in vivo administration of anti-CD3, interleukin-2, and tumor necrosis factor-a in mice. Surg. Forum, 40:423-425, 1989.
  100. Ajani, J.A., Roth, J.A., Ryan, B., McMurtrey, M., Rich, T.A., Jackson, D.E., Abbruzzese, J.L., Levin, B., DeCaro, L., and Mountain, C. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J. Clin. Oncol., 8:1231-1238, 1990.
  101. Browne, M.J., Potter, D., Gress, J., Cotton, D., Hiemenz, J., Thaler, M., Hathorn, J., Brower, S., Gill, V., Glastein, E., Pass, H., Roth, J.A., Wesley, R., Shelhamer, J., and Pizzo, P. A randomized trial of open lung biopsy versus empiric antimicrobial therapy in cancer patients with diffuse pulmonary infiltrates. J. Clin. Oncol., 8:222-229, 1990.
  102. Perry, R.R., Venzon, D., Roth, J.A., and Pass, H.I. Survival after surgical resection for high-grade chest wall sarcomas. Ann. Thorac. Surg., 49:363-369, 1990.
  103. Putnam, J.B. Jr., Lammermeier, D.E., Colon, R., McMurtrey, M.J., Ali, M.K., and Roth, J.A. Predicted pulmonary function and survival after pneumonectomy for primary lung carcinoma. Ann. Thorac. Surg., 49:909-915, 1990.
  104. Schneider, P.M., Hung, M.-C., Ames, R.S., Putnam, E.A., Akpakip, B., and Roth, J.A. A novel alteration in the epidermal growth factor receptor gene is frequently detected in human non-small cell lung cancer. Lung Cancer, 6:65-72, 1990.
  105. Yang, S.C., Fry, K.D., Grimm, E.A., and Roth, J.A. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin-2 and tumor necrosis factor-a. Arch. Surg., 125:220-225, 1990.
  106. Yang, S.C., Owen-Schaub, L.B., Roth, J.A., and Grimm, E.A. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor-a. Cancer Res., 50:3526-3532, 1990.
  107. Yang, S.C., Owen-Schaub, L., Mendiguren-Rodriquez, A., Grimm, E.A., Hong, W.K., and Roth, J.A. Combination immunotherapy for non-small cell lung cancer. Results using interleukin-2 and tumor necrosis factor-a. J. Thorac. Cardiovasc. Surg., 99:8-13, 1990.
  108. Yang, S.C., Grimm, E.A., and Roth, J.A. Effects of low dose OKT3 induction on the anti-tumor immune response in cancer patients receiving interleukin-2 (IL-2) and tumor necrosis factor-(TNF). Surg. Forum, 41:434-436, 1990.
  109. Casson, A.G., Mukhopadhyay, T., Cleary, K.R., Ro, J.Y., Levin, B., and Roth, J.A. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res., 51:4495-4499, 1991.
  110. Casson, A.G., Putnam, J.B., Natarajan, G., Johnston, D.A., Mountain, C., McMurtrey, M., and Roth, J.A. Efficacy of pulmonary metastasectomy for recurrent soft tissue sarcoma. J. Surg. Oncol., 47:1-4, 1991.
  111. Ellerbroek, N.A., Fossella, F.V., Rich, T.A., Ajani, J.A., Komaki, R., Roth, J.A., and Holoye, P.Y. Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 20:351-355, 1991.
  112. Gorenstein, L.A., Putnam, J.B., Natarajan, G., Balch, C.A., and Roth, J.A. Improved survival after resection of pulmonary metastases from malignant melanoma. Ann Thorac Surg, 52:204-210, 1991.
  113. Lanza, L.A., Putnam, J.B. Jr., Benjamin, R.S., and Roth, J.A. Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases. Ann. Thorac. Surg., 51:219-224, 1991.
  114. Lazenby, A.W., Yang, S.C., Sniege, N., Grimm, E.A., and Roth, J.A. Regression of radiation and chemotherapy resistant non-small cell lung cancer treated with combination immunotherapy. Cancer Bull., 43:181-184, 1991.
  115. Lazenby, A.W., Owen-Schaub, L.B., Crump, W.L., Grimm, E.A., and Roth, J.A. IL-1 synergizes with interleukin-2 in the generation of cytotoxic lymphocytes via a tumor necrosis factor mediated pathway. Surg. Forum, 42:472-475, 1991.
  116. Mukhopadhyay, T., Tainsky, M., Cavender, A.C., and Roth, J.A. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res., 51:1744-1748, 1991.
  117. Pass, H.I., Evans, S., Matthews, W.A., Perry, R., Venzon, D., Roth, J.A., and Smith, P. Photodynamic therapy of oncogene-transformed cells. J. Thorac. Cardiovasc. Surg., 101:795-799, 1991.
  118. Pogrebniak, H.W., Roth, J.A., Steinberg, S.M., Rosenberg, S.A., and Pass, H.I. Re-operative pulmonary resection in patients with metastatic soft tissue sarcoma. Ann. Thorac. Surg., 52:197-203, 1991.
  119. Pogrebniak, H.W., Matthews, W., Black, C., Russo, A., Smith, P., Roth, J.A., and Pass, H.I. Targeted phototherapy with sensitizer-monoclonal antibody and light. Surg. Forum, 42:447-449, 1991.
  120. Robey-Cafferty, S.S., Ajani, J.A., Ota, D.M., Roth, J.A., and Bruner, J.M. Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. Arch. Pathol. Lab. Med., 115:807-812, 1991.
  121. Yang, S.C., Grimm, E.A., and Roth, J.A. Biologic therapy for lung cancer. Cancer Bull., 43:100-108, 1991.
  122. Yang, S.C., Grimm, E.A., Parkinson, D.R., Carinas, J., Fry, K.D., Mendiguren-Rodriguez, A., Licciardello, J., Owen-Schaub, L.B., Hong, W.K., and Roth, J.A. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor-a in patients with advanced non-small cell lung cancer: a phase I trial. Cancer Res., 51:3669-3676, 1991.
  123. Yang, S.C., Grimm, E.A., and Roth, J.A. Immunotherapy of lung cancer. Chest Surg. Clin. N. Am., 1:191-204, 1991.
  124. Yang, S.C., Fry, K.D., Grimm, E.A., and Roth, J.A. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-a combination immunotherapy. J. Immunol., 10:326-335, 1991.
  125. Zatopek, N.K., Holoye, P.Y., Ellerbroek, N.A., Hong, W.K., Roth, J.A., Ryan, M.B., Komaki, R., Pang, A.C., and Glisson, B.S. Resectability of small-cell lung cancer following induction chemotherapy in patients with limited disease (stage II-IIIB). Am. J. Clin. Oncol., 14:427-432, 1991.
  126. Ajani, J.A., Ryan, B., Rich, T.A., McMurtrey, M., Roth, J.A., DeCaro, L., Levin, B., and Mountain, C. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur. J. Cancer, 28A:880-884, 1992.
  127. Casson, A.G., Putnam, J.B., Natarajan, G., Johnston, D.A., Mountain, C., McMurtrey, M., and Roth, J.A. Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer, 69 :662-668, 1992.
  128. Cybulsky, I., Lanza, L., Ryan, M., Putnam, J.B. Jr., McMurtrey, M.J., and Roth, J.A. Prognostic significance of computed tomography in resection N2 lung cancer. Ann Thorac Surg, 54:533-537, 1992.
  129. Georges, R.N., Zhang, Y., Mukhopadhyay, T., and Roth, J.A. Retroviral mediated gene transfer of antisense K-ras suppresses tumor growth in an orthotopic lung cancer model. Surg. Forum, 43:490-491, 1992.
  130. Lanza, L.A., Natarajan, G., Roth, J.A., and Putnam, J.B. Jr. Long-term survival after resection of pulmonary metastases from carcinoma of the breast. Ann. Thorac. Surg., 54:244-248, 1992.
  131. Lazenby, A.W., Roth, J.A., Owen-Schaub, L.B., and Grimm, E.A. IL-1 synergy with IL-2 in the generation of lymphokine activated killer cells is mediated by TNF-a and b (lymphotoxin). Cytokine, 4:479-487, 1992.
  132. Morice, R.C., Peters, E.J., Ryan, M.B., Putnam, J.B., Ali, M.K., and Roth, J.A. Exercise testing in the evaluation of patients at high risk for complications from lung resection. Chest, 101:356-363, 1992.
  133. Mukhopadhyay, T., and Roth, J.A. A simple and efficient method for isolation of DNA fragment from agarose gel. Nucleic Acids Res., 19:6656-6656, 1992.
  134. Putnam, E.A., Yen, N., Gallick, G.E., Steck, P.A., Fang, K., Akpakip, B., Gazdar, A.F., and Roth, J.A. Autocrine growth stimulation by transforming growth factor-a in human non-small cell lung cancer. Surg. Oncol., 1:49-60, 1992.
  135. Roth, J.A. New approaches to treating early lung cancer. Cancer Res., 52:S2652-S2657, 1992.
  136. Roth, J.A. Molecular and cell biology of lung cancer. Radiat. Res., 2:368-374, 1992.
  137. Yang, S.C., Grimm, E.A., and Roth, J.A. Combination immunotherapy for advanced lung cancer. J. Natl. Cancer Inst., 13:197-201, 1992.
  138. Ajani, J.A., Roth, J.A., Ryan, M.B., Putnam, J.B., Pazdur, R., Levin, B., Gutterman, JU, and McMurtrey, M. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J. Clin. Oncol., 11:22-28, 1993.
  139. Cai, D.W., Mukhopadhyay, T., Liu, Y., Fujiwara, T., and Roth, J.A. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum. Gene Ther., 4:617-624, 1993.
  140. Chung, K.Y., Mukhopadhyay, T., Kim, J., Casson, A., Ro, J.Y., Goepfert, H., Hong, W.K., and Roth, J.A. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res., 53:1676-1683, 1993.
  141. Fujiwara, T., Grimm, E.A., Mukhopadhyay, T., Cai, D.W., Owen-Schaub, L.B., and Roth, J.A. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res., 53:4129-4133, 1993.
  142. Georges, R.N., Mukhopadhyay, T., Zhang, Y., Yen, N., and Roth, J.A. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res., 53:1743-1746, 1993.
  143. Maxwell, S.A., and Roth, J.A. Binding of cellular proteins to a conformational domain of tumor suppressor protein p53. Oncogene, 8:3421-3426, 1993.
  144. Mukhopadhyay, T., and Roth, J.A. A codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53. Cancer Res., 53:4362-4366, 1993.
  145. Mukhopadhyay, T., and Roth, J.A. Silicone lubricant enhances recovery of nucleic acids after phenol-chloroform extraction. Nucleic Acids Res., 21:781-782, 1993.
  146. Pogrebniak, H.W., Matthews, W., Black, C., Russo, A., Mitchell, J.B., Smith, P., Roth, J.A., and Pass, H.I. Targeted phototherapy with sensitizer-monoclonal antibody conjugate and light. Surg. Oncol., 2:31-42, 1993.
  147. Putnam, J.B. Jr., Suell, D.M., Natarajan, G., and Roth, J.A. Extended resection of pulmonary metastases: Is the risk justified Ann. Thorac. Surg., 55:1440-1446, 1993.
  148. Srinivasan, R., Roth, J.A., and Maxwell, S.A. Sequence-specific interaction of a conformational domain pf p53 with DNA. Cancer Res., 53:5361-5364, 1993.
  149. Zhang, W.W., Fang, X., Branch, C.D., Mazur, W., French, B.A., and Roth, J.A. Generation and identification of recombinant adenovirus by lipsome-mediated transfection and PCR analysis. Biotechniques, 15:868-872, 1993.
  150. Zhang, Y., Mukhopadhyay, T., Donehower, L.A., Georges, R.N., and Roth, J.A. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum. Gene Ther., 4:451-460, 1993.
  151. Casson, A.G., Manolopoulos, B., Troster, M., Kerkvliet, N., Omalley, F., Inculet, R., Finley, R., and Roth, J.A. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Am. J. Surg., 167:52-57, 1994.
  152. Drazan, K.E., Shen, X.D., Csete, M.E., Zhang, W.W., Roth, J.A., Busuttil, R.W., and Shaked, A. In vivo adenoviral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection. Surgery, 116:197-204, 1994.
  153. Fujiwara, T., Grimm, E.A., Mukhopadhyay, T., Zhang, W.W., Owen-Schaub, L.B., and Roth, J.A. Induction of chemosensitivity in human lung cancer cells in vivo by adenoviral-mediated transfer of the wild-type p53 gene. Cancer Res., 54:2287-2291, 1994.
  154. Fujiwara, T., Mukhopadhyay, T., Cai, D.W., Morris, D.K., Roth, J.A., and Grimm, E.A. Retroviral-mediated transduction of p53 gene increases TGF-b expression in a human glioblastoma cell line. Int. J. Cancer, 56:834-839, 1994.
  155. Fujiwara, T., Grimm, E.A., Mukhopadhyay, T., Zhang, W.W., Owen-Schaub, L.B., and Roth, J.A. Induction of chemosensitivity in human cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Surg. Forum, 45:524-526, 1994.
  156. Green, M.R., Cox, J.D., Ardizzoni, A., Arriagada, R., Bureau, G., Darwish, S., Deneffe, G., Fukuoka, M., Joseph, D., Komaki, R., and Roth, J.A. Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): A consensus report. Lung Cancer, 11:S11-S13, 1994.
  157. Green, M.R., Ginsberg, R., Ardizzoni, A., Choi, N., Darwish, S., Fukuoka, M., Giner, V., Grunenwald, D., Harper, P., Kho, S., and Roth, J.A. Induction therapy for stage III NSCLC: A consensus report. Lung Cancer, 11:S9-S10, 1994.
  158. Liu, T.J., Zhang, W.W., Taylor, D.L., Roth, J.A., Goepfert, H., and Clayman, G.L. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res., 54:3662-3667, 1994.
  159. Mukhopadhyay, T., and Roth, J.A. Visualization of RNA in gel by shortwave UV epi-illumination without staining. Biotechniques, 17:619-620, 1994.
  160. Pass, H.I., Sindelar, W.F., Kinsella, T.J., Deluca, A.M., Barnes, M., Kurtzman, S., Hoekstra, H., Tochner, Z., Roth, J.A., and Glatstein, E. Delivery of intraoperative radiation therapy (IORT) after pneumonectomy: experimental observations and early clinical results. Ann. Thorac. Surg., 58:269-270, 1994.
  161. Putnam, J.B. Jr., Suell, D.M., McMurtrey, M.J., Ryan, M.B., Walsh, G.L., Natarajan, G., and Roth, J.A. Comparison of three techniques of esophagectomy within a residency training program. Ann. Thorac. Surg., 57:319-325, 1994.
  162. Roth, J.A., Fossella, F., Komaki, R., Ryan, M.B., Putnam, J.B. Jr., Lee, J.S., Dhingra, H., DeCaro, L., Chasen, M., McGavran, M., Atkinson, E.N., and Hong, W.K. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst., 86:673-680, 1994.
  163. Roussel, E., Gingras, M.C., Ro, J.Y., Branch, C., and Roth, J.A. Loss of a1b1 and reduced expression of other b1 integrins and CAM in lung adenocarcinoma compared with pneumocytes. J. Surg. Oncol., 56:198-208, 1994.
  164. Shin, D.M., Kim, J., Ro, J.Y., Hittelman, J., Roth, J.A., Hong, W.K., and Hittelman, W.N. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res., 54:321-326, 1994.
  165. Tockman, M.S., Erozan, Y.S., Gupta, P.K., Piantadosi, S., Mulshine, J.L., Ruckdeschel, and Roth, J.A. The early detection of second primary lung cancers by sputum immunostaining. Chest, 106:385s-390s, 1994.
  166. Walsh, G.L., Morice, R.C., Putnam, J.B. Jr., Nesbitt, J.C., McMurtrey, M.J., Ryan, M.B., Reising, J.M., Willis, K.M., Morton, J.D., and Roth, J.A. Resection of lung cancer is justified in high-risk patients selected by exercise oxygen consumption. Ann. Thorac. Surg., 58:704-711, 1994.
  167. Zhang, W.W., Fang, X., Mazur, W., French, B.A., Georges, R.N., and Roth, J.A. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther., 1:5-13, 1994.
  168. Ajani, J.A., Roth, J.A., Putnam, J.B., Walsh, G., Lynch, P.M., Roubein, L.D., Ryan, M.B., Natarajan, G., and Gould, P. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastroesophageal junction. Eur. J. Cancer, 31A:665-670, 1995.
  169. Cai, D.W., Mukhopadhyay, T., and Roth, J.A. Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther., 2:199-205, 1995.
  170. Clayman, G.L., El-Naggar, A.K., Roth, J.A., Zhang, W.W., Goepfert, H., Taylor, D.L., and Liu, T.-J. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res., 55:1-6, 1995.
  171. Cristiano, R.J., Mukhopadhyay, T., Zhang, W.W., and Roth, J.A. Gene therapy for modification of oncogene and tumor suppressor gene expression in cancer. Documenta, 2:17-35, 1995.
  172. Ding, Z.M., Cristiano, R.J., Roth, J.A., Takacs, B., and Kuo, M.T. Malarial circumsporozoite protein is a novel gene delivery vehicle to primary hepatocyte cultures and cultured cells. J. Biol. Chem., 270:3667-3676, 1995.
  173. Gingras, M.C., Roussel, E., Roth, J.A., and Moser, R.P. Little expression of cytokine mRNA by fresh tumour-infiltrating mononuclear leukocytes from glioma and lung adenocarcinoma. Cytokine, 7:580-588, 1995.
  174. Jin, X., Nguyen, D., Zhang, W.W., Kyritsis, A.P., and Roth, J.A. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res., 55:3250-3253, 1995.
  175. Jin, X., Wu, X., Roth, J.A., Amos, C.I., King, T.M., Branch, C., Honn, S.E., and Spitz, M.R. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis, 16:2205-2208, 1995.
  176. Kim, Y.H., Ajani, J.A., Ota, D.M., Lynch, P., and Roth, J.A. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinomas of the esophagus and stomach and stomach. Cancer, 75:451-456, 1995.
  177. Komaki, R., Shin, D.M., Glisson, B.S., Fossella, F.V., Murphy, W.K., Garden, A.S., Oswald, M.J., Hong, W.K., Roth, J.A., and Peters, L.J. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 31:807-811, 1995.
  178. Mukhopadhyay, T., Roth, J.A., and Maxwell, S.A. Altered expression of the p50 subunit of the NF-kB transcription factor complex in non-small cell lung carcinoma. Oncogene, 11:999-1003, 1995.
  179. Nesbitt, J.C., Putnam, J.B. Jr., Walsh, G.L., Roth, J.A., and Mountain, C.F. Survival in early-stage non-small cell lung cancer. Ann. Thorac. Surg., 60:466-472, 1995.
  180. Nguyen, D., Wiehle, S., Cristiano, R., and Roth, J.A. Efficient gene delivery to malignant cells by a conjugated adenovirus/DNA complex. Surg. Forum, 46:475-477, 1995.
  181. Owen-Schaub, L.B., Zhang, W., Cusack, J.C., Angelo, L.S., Santee, S.M., Fujiwara, T., Roth, J.A., Deisseroth, A.B., Zhang, W.W., Kruzel, E., and Radinsky, R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol., 15:3032-3040, 1995.
  182. Putnam, J.B., Jr., and Roth, J.A. Surgical treatment for pulmonary metastases from sarcoma. Hematol. Oncol. Clin. North Am., 9:869-887, 1995.
  183. Roussel, E., Gingras, M.C., Grimm, E.A., and Roth, J.A. High expression of adhesion molecules/activation markers with little interleukin-2, interferon g, and tumor necrosis factor b gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma. Cancer Immunol. Immunother., 41:1-9, 1995.
  184. Soysal, O., Walsh, G.L., Nesbitt, J.C., McMurtrey, M.J., Roth, J.A., and Putnam, J.B., Jr. Resection of sternal tumors: extent, reconstruction, and survival. Ann. Thorac. Surg., 60:1353-1359, 1995.
  185. Spitz, M.R., Hsu, T.C., Wu, X., Fueger, J.J., Amos, C.I., and Roth, J.A. Mutagen sensitivity as a biological marker of lung cancer risks in African Americans. Cancer Epidemiol. Biomarkers Prev., 4:99-103, 1995.
  186. Walsh, G.L., O'Connor, M., Willis, K.M., Milas, M., Wong, R., Nesbitt, J.C., Putnam, J.B., and Roth, J.A. Is follow-up of lung cancer patients after resection medically indicated and cost effective? Ann. Thorac. Surg., 60:1563-1572, 1995.
  187. Wang, J., Bucana, C.D., Roth, J.A., and Zhang, W.W. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther., 2:9-17, 1995.
  188. Zhang, W.W., Koch, P.E., and Roth, J.A. Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. Biotechniques, 18:444-447, 1995.
  189. Zhang, W.W., Alemany, R., Wang, J., Koch, P.E., Ordonez, N.G., and Roth, J.A. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum. Gene Ther., 6:155-164, 1995.
  190. Zhang, W.W. and Roth, J.A. Anti-oncogene and tumor suppressor gene therapy - examples of lung cancer animal model. In Vivo, 8:755-770, 1995.
  191. Alemany, R., Ruan, S., Kataoka, M., Koch, P.E., Mukhopadhyay, T., Cristiano, R.J., Roth, J.A., and Zhang, W.W. Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther., 3:296-301, 1996.
  192. Cristiano, R.J. and Roth, J.A. Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther., 3:4-10, 1996.
  193. Cusack, J.C., Spitz, F.R., Nguyen, D., Zhang, W.W., Cristiano, R.J., and Roth, J.A. High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cancer Gene Ther., 3:245-249, 1996.
  194. Eicher, S.A., Clayman, G.L., Liu, T.J., Shillitoe, E.J., Storthz, K.A., Roth, J.A., and Lotan, R. Evaluation of topical gene therapy for head and neck squamous cell carcinoma in an organotypic model. Clin. Cancer Res., 2:1659-1664, 1996.
  195. Gomez-Manzano, C., Fueyo, J., Kyritsis, A.P., Steck, P.A., Roth, J.A., McDonnell, T.J., Steck, K.D., Levin, V.A., and Yung, W.K. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res., 56:694-699, 1996.
  196. Hamada, K., Alemany, R., Zhang, W.W., Hittelman, W.N., Lotan, R., Roth, J.A., and Mitchell, M.F. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res., 56:3047-3054, 1996.
  197. Hamada, K., Zhang, W.W., Alemany, R., Wolf, J., Roth, J.A., and Mitchell, M.F. Growth inhibition of human cervical cancer cells with the recombinant adenovirus p53 in vitro. Gynecol. Oncol., 60:373-379, 1996.
  198. Hamada, K., Sakaue, M., Alemany, R., Zhang, W.W., Horio, Y., Roth, J.A., and Mitchell, M.F. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol. Oncol., 63:219-227, 1996.
  199. Hamada, M., Fujiwara, T., Hizuta, A., Gochi, A., Naomoto, Y., Takakura, N., Takahashi, K., Roth, J.A., Tanaka, N., and Orita, K. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J. Cancer Res. Clin. Oncol., 122:360-365, 1996.
  200. Horio, Y., Chen, A., Rice, P., Roth, J.A., Malkinson, A.M., and Schrump, D.S. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol. Carcinog., 17:217-223, 1996.
  201. Maxwell, S.A., Roth, J.A., and Mukhopadhyay, T. Analysis of phosphorylated isoforms of the p53 tumor suppressor protein in human lung carcinoma cells undergoing apoptosis. Electrophoresis, 17:1772-1775, 1996.
  202. Mitchell, M.F., Hamada, K., Sastry, K.J., Sarkar, A., Tortolero-Luna, G., Wharton, J.T., and Roth, J.A. Transgene expression in the rhesus cervix mediated by an adenovirus expressing beta-galactosidase. Am. J. Obstet. Gynecol., 174:1094-1101, 1996.
  203. Mukhopadhyay, T. and Roth, J.A. Functional inactivation of p53 by antisense RNA induces invasive ability of lung carcinoma cells and downregulates cytokeratin synthesis. Anticancer Res., 16:1683-1689, 1996.
  204. Mukhopadhyay, T. and Roth, J.A. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines. Anticancer Res., 16:105-112, 1996.
  205. Mukhopadhyay, T., Roth, J.A., and Maxwell, S.A. Induction of p53 DNA-binding activity by tumor necrosis factor-?. Int. J. Oncol., 9:715-720, 1996.
  206. Mukhopadhyay, T., and Roth, J.A. WAF1 expression is independent of p53 gene alterations and protein expression in human lung cancer cells. Int. J. Oncol., 9:405-410, 1996.
  207. Nguyen, D.M., Spitz, F.R., Yen, N., Cristiano, R.J., and Roth, J.A. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J. Thorac. Cardiovasc. Surg., 112:1372-1377, 1996.
  208. Roth, J.A. Clinical Protocol: modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC). Hum. Gene Ther., 7:875-889, 1996.
  209. Roth, J.A. Clinical Protocol: modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum. Gene Ther., 7:1013-1030, 1996.
  210. Roth, J.A. Clinical protocol: modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wildtype (normal) p53. Hum. Gene Ther., 7:861-874, 1996.
  211. Roth, J.A., Nguyen, D., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Ferson, D.Z., Hong, W.K., Komaki, R., Lee, J.J., Nesbitt, J.C., Pisters, K.M.W., Putnam, J.B., Schea, R., Shin, D.M., Walsh, G.L., Dolormente, M.M., Han, C.-I., Martin, F.D., Yen, N., Xu, K., Stephens, L.C., McDonnell, T.J., Mukhopadhyay, T., and Cai, D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med., 2:985-991, 1996.
  212. Schneider, P.M., Casson, A.G., Levin, B., Garewal, H.S., Hoelscher, A.H., Becker, K., Dittler, H.J., Cleary, K.R., Troster, M., Siewert, J.R., and Roth, J.A. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J. Thorac. Cardiovasc. Surg., 111:323-333, 1996.
  213. Schrump, D.S., Chen, G.A., Consuli, U., Jin, X.M., and Roth, J.A. Inhibition of esophageal cancer proliferation by adenoviral mediated delivery of p16INK4. Cancer Gene Ther., 3:357-364, 1996.
  214. Spitz, F.R., Nguyen, D., Skibber, J.M., Cusack, J., Roth, J.A., and Cristiano, R.J. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res., 16:3415-3422, 1996.
  215. Spitz, F.R., Nguyen, D., Skibber, J.M., Meyn, R.E., Cristiano, R.J., and Roth, J.A. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin. Cancer Res., 2:1665-1671, 1996.
  216. Spitz, F.R., Nguyen, D., Skibber, J.M., Meyn, R.E., Cristiano, R.J., and Roth, J.A. Enhancement of radiation sensitivity of colorectal cancer cells by adenovirus-mediated p53 gene therapy. Surg. Forum, 47:481-484, 1996.
  217. Bouvet, M., Ellis, L.M., Liu, W., Fang, B., and Roth, J.A. Adenovirally mediated wild-type p53 gene therapy downregulates vascular endothelial growth factor expression in human colon cancer. Surg. Forum, 48:806-809, 1997.
  218. Fang, B., Koch, P., Bouvet, M., Ji, L., and Roth, J.A. A packaging system for SV40 vectors without viral coding sequences. Anal. Biochem., 254:139-143, 1997.
  219. Fang, B., Koch, P.E., and Roth, J.A. Diminishing adenovirus gene expression and viral replication by promoter replacement. J. Virol., 71:4798-4803, 1997.
  220. Ferson, D.Z., Nesbitt, J.C., Nesbitt, K.K., Walsh, G.L., Putnam, J.B., Jr., Schrump, D.S., Johansen, M.J., Jones, R.L., and Roth, J.A. The laryngeal mask airway - a new standard for airway evaluation in thoracic surgery. Ann. Thorac. Surg., 63:768-772, 1997.
  221. Kagawa, S., Fujiwara, T., Hizuta, A., Yasuda, T., Zhang, W.W., Roth, J.A., and Tanaka, N. p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells. Oncogene, 15:1903-1909, 1997.
  222. Kataoka, M., Komaki, R., and Roth, J.A. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Exp. Med., 15:251-254, 1997.
  223. Mukhopadhyay, T. and Roth, J.A. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene, 14:379-384, 1997.
  224. Nguyen, D.M., Wiehle, S.A., Koch, P.E., Branch, C., Yen, N., Roth, J.A., and Cristiano, R.J. Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex. Cancer Gene Ther., 4:191-198, 1997.
  225. Nguyen, D.M., Wiehle, S.A., Roth, J.A., and Cristiano, R.J. Gene delivery into malignant cells in vivo by a conjugated adenovirus/DNA complex. Cancer Gene Ther., 4:183-190, 1997.
  226. Ogawa, N., Fujiwara, T., Kagawa, S., Nishizaki, M., Morimoto, Y., Tanida, T., Hizuta, A., Yasuda, T., Roth, J.A., and Tanaka, N. Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int. J. Cancer, 73:367-370, 1997.
  227. Overholt, S.M., Liu, T.-J., Taylor, D.L., Wang, M., El-Naggar, A.K., Shillitoe, E., Adler-Storthz, K., Zhang, W.-W., Roth, J.A., and Clayman, G.L. Head and neck squamous cell growth suppression using adenovirus-p53-FLAG--a potential marker for gene therapy trials. Clin. Cancer Res., 3:185-191, 1997.
  228. Tockman, M.S., Mulshine, J.L., Piantodosi, S., Erozan, Y.S., Gupta, P.K., Ruckdeschel, J.C., Taylor, P.R., Zhukov, T., Zhou, W.-H., Qiao, Y.-L., Yao, S.-X., and Roth, J.A. Prospective detection of preclinical lung cancer: Results from 2 studies of heterogeneous nuclear ribonucloprotein A2/B1 overexpression. Clin. Cancer Res., 3:2237-2246, 1997.
  229. Walsh, G.L., Gokaslan, Z.L., McCutcheon, I.E., Mineo, M.T., Yasko, A.W., Swisher, S.G., Schrump, D.S., Nesbitt, J.C., Putnam, J.B. Jr., and Roth, J.A. Anterior approaches to the thoracic spine in patients with cancer - indications and results. Ann. Thorac. Surg., 64:1611-1618, 1997.
  230. Bouvet, M., Ellis, L.M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C.D., Fang, B., Lee, J.J., and Roth, J.A. Adenovirus-mediated wild-type p53 gene transfer downregulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res., 58:2288-2292, 1998.
  231. Bouvet, M., Fang, B., Ekmekcioglu, S., Ji, L., Bucana, C.D., Hamada, K., Grimm, E.A., and Roth, J.A. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther., 5:189-195, 1998.
  232. Clayman, G.L., El-Naggar, A.K., Lippman, S.M., Henderson, Y.C., Frederick, M., Merritt, J.A., Zumstein, L.A., Timmons, T.M., Liu, T.-J., Ginsberg, L., Roth, J.A., Hong, W.K., Bruso, P., and Goepfert, H. Adenovirus mediated p53 tumor transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol., 16:2221-2232, 1998.
  233. Fang, B., Ji, L., Bouvet, M., and Roth, J.A. Evaluation of GAL4/TATA in vivo: induction of transgene expression by adenovirally mediated gene codelivery. J. Biol. Chem., 273:4972-4975, 1998.
  234. Fang, X.J., Jin, X.M., Xu, H.J., Liu, L., Peng, H.Q., Hogg, D., Roth, J.A., Yu, Y.H., Xu, F.J., Bast, R.C., and Mills, G.B. Expression of p16 induces transcriptional downregulates of the RB gene. Oncogene, 16:1-8, 1998.
  235. Mukhopadhay, T. and Roth, J.A. Isolation of total RNA from tissues or cell lines. Methods Mol. Biol., 86:55-59, 1998.
  236. Mukhopadhyay, T. and Roth, J.A. Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene, 17:241-246, 1998.
  237. Roth, J.A., Swisher, S.G., Merritt, J.A., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., El-Naggar, A.K., Fossella, F.V., Glisson, B.S., Hong, W.K., Khuri, F.R., Kurie, J.M., Nesbitt, J.C., Pisters, K.M., Putnam, J.B., Jr., Schrump, D.S., Shin, D.M., and Walsh, G.L. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin. Oncol., 25:33-37, 1998.
  238. Shin, D.M., Walsh, G.L., Komaki, R., Putnam, J.B., Nesbitt, J., Ro, J.Y., Shin, H.J.C., Ki, K.H., Wimberly, A., Pisters, K.M.W., Schrump, D., Gregurich, M.A., Cox, J.D., Roth, J.A., and Hong, W.K. A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann. Intern. Med., 129:100-104, 1998.
  239. Tada, M., Sakuma, S., Iggo, R.D., Saya, H., Sawamura, Y., Fujiwara, T., and Roth, J.A. Monitoring adenoviral p53 transduction efficiency by yeast functional assay. Gene Ther., 5:339-344, 1998.
  240. Mukhopadhyay, T., Multani, A.S., Roth, J.A., and Pathak, S. Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-medited apoptosis. Oncongene, 17:901-906, 1998.
  241. Roth, J.A., Atkinson, E.N., Fossella, F., Komaki, R., Ryan, M.B., Putnam, J.B., Jr., Lee, J.S., Dhingra, H., De Caro, L., Chasen, M., and Hong, W.K. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer, 21: 1-6, 1998.
  242. Xu, B., Wiehle, S., Roth, J.A., and Cristiano, R.J. The contribution of poly-L-lysine, epidermal growth factor, and streptavidin to EGF/PLL/DNA polyplex formation. Gene Ther., 5:1235-1243, 1998.
  243. Kataoka, M., Schumacher, G., Cristiano, R.J., Atkinson, E.N., Roth, J.A., and Mukhopadhyay, T. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. Cancer Res., 58:4761-4765, 1998.
  244. Kelsen, D.P., Ginsberg, R., Pajak, T.F., Sheahan, D.G., Gunderson, L., Mortimer, J., Estes, N., Haller, D.G., Ajani, J., Kocha, W., Minsky, B.D., and Roth, J.A. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N. Engl. J. Med., 339:1979-1984, 1998.
  245. Roth, J.A. Restoration of tumor suppressor gene expression for cancer. Forum (Genova), 8:368-376, 1998.
  246. Nguyen, D., Wiehle, S., Cristiano, R., Roth, J.A., Efficient Gene Delivery to Malignant Cells by a Conjugated Adenovirus/DNA Complex. Surgical Forum, 81st Annual Clinical Congress, XLVI:475-477, 1998.
  247. Bouvet, M., Bold, R.J., Lee, J., Evans, D.B., Abbruzzese, J.L., Chiao, P.J., McConkey, D.J., Chandra, J., Chada, S., Fang, B., and Roth, J.A. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann. Surg. Oncol., 5:681-688, 1998.
  248. Cristiano, R.J., Xu, B., Nguyen, D., Schumacher, G., Kataoka, M., Spitz, F.R., and Roth, J.A. Viral and nonviral gene delivery vectors for cancer gene therapy. Cancer Detect. Prev., 22:445-454, 1998.
  249. Fang, B., Xu, B., Koch, P., and Roth, J.A. Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells. Gene Ther., 5:1420-1424, 1998.
  250. Ji, L., Fang, B., and Roth, J.A. A rapid, sensitive, and non-radioactive method for assay of FHIT Ap3A hydrolase activity by fluorescence thin-layer chromatographic image analysis. Anal. Biochem., 271:114-116, 1999.
  251. Ji, L., Bouvet, M., Price, R., Roth, J.A., and Fang, B. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement. Gene Ther., 6:393-402, 1999.
  252. Schumacher, G., Kataoka, M., Roth, J.A., and Mukhopadhyay, T. Potent antitumor activity of 2-Methoxyestradiol in human pancreatic cancer cell lines. Clin. Cancer Res., 5:493-499, 1999.
  253. Swisher, S.G., Roth, J.A., Nemunaitis, J., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Connors, D.G., El-Naggar, A.K., Fossella, F., Glisson, B.S., Hong, W.K., Khuri, F.R., Kurie, J.M., Lee, J.J., Lee, J.S., Mack, M., Merritt, J.A., Nguyen, D.M., Nesbitt, J.C., Perez-Soler, R., Pisters, K.M.W., Putnam, J.B., Jr., Richli, W.R., Savin, M., Schrump, D.S., Shin, D.M., Shulkin, A., Walsh, G.L., Wait, J., Weill, D., and Waugh, M.K.A. Adenoviral-mediated p53 gene transfer in advanced non-small cell lung cancer. J. Natl. Cancer Inst., 91:763-771, 1999.
  254. Nishizaki, M., Fujiwara, T., Tanida, T., Hizuta, A., Nishimori, H., Tokino, T., Nakamura, Y., Bouvet, M., Roth, J.A., and Tanka, N. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin. Cancer Res., 5:1015-1023, 1999
  255. Beaupre, D., Talpaz, M., Marini, F., Cristiano, R., Roth, J.A., Estrov, Z., Albitar, M., Freedman, M., and Kurzrock, R. Autocrine interleukin - 1b production in leukemia: evidence for the involvement of mutatated RAS. Cancer Res., 59:2971-2980, 1999
  256. Ji, L., Fang, B., Yen, N., Fong, K., Minna, J.D., and Roth, J.A. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated FHIT gene overexpression. Cancer Res., 59:3333-3339, 1999
  257. Mohan, P.M., Chintala, S.K., Mohanam, S., Gladson, C.L., Kim, E.S., Gokaslan, Z.L., Lakka, S.S., Roth, J.A., Fang, B., Sawaya, R., Kyritsis, A.P., Rao, J.S. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor supresses glioma invasion and tumor growth. Cancer Res., 59:3369-3373, 1999
  258. Kagawa, S., Fujiwara, T., Kadowaki, Y., Fukazawa, T., Sok-Joo, R., Roth, J.A., and Tanaka, N. Overexpression of the p21(sdi1) gene induces senescence-like state in human cancer cells: implication for senescence-directed molecular therapy for cancer. Cell Death & Differentiation, 6:765-772, 1999.
  259. Wolf, J. K., Mills, G. B., Bazzet, L., Bast, R.C., Roth, J.A., and Gershenson, D. M. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol. Oncol., 75:261-266, 1999
  260. Roth, J.A., Swisher, S.G., and Meyn, R.E. p53 tumor suppressor gene therapy for cancer. Oncology, 13:148-154, 1999.
  261. Kadowaki, Y., Fujiwara, T., Fukazawa, T., Shao, J., Yasuda, T., Itoshima, T., Kagawa, S., Hudson, L.G., Roth, J.A., and Tanka, N. Induction of differentiation-dependent apoptosis in human esophageal squamous cell carcinoma by adenovirus-mediated p21sdi1 gene transfer. Clin. Cancer Res., 5:4233-4241, 1999.
  262. Gandhi, S., Walsh, G.L., Komaki, R., Gokaslan, Z.L., Nesbitt, J.C., Putnam, J.B., Jr., Roth, J.A., Merriman, K.W., McCutcheon, I.E., Munden, R.F., and Swisher, S.G. A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion. Ann. Thorac. Surg., 68:1778-1785, 1999.
  263. Fukazawa, T., Fujiwara, T., Morimoto, Y., Shao, J., Nishizaki, M., Kadowaki, Y., Hizuta A., Owen-Schaub, L.B., Roth, J.A., and Tanka, N. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Oncogene, 18:2189-2199, 1999.
  264. Pearson, A.S., Koch, P.E., Atkinson, N., Xiong, M., Finberg, R.W., Roth, J.A., and Fang.B. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin. Cancer Res., 5:4208-4213, 1999.
  265. Pataer, A., Fang, B., Yu, R., Kagawa, S., Hunt, K.K., McDonnell, T.J., Roth, J.A., and Swisher, S.G. Adenoviral bak overexpression mediates caspase-dependent tumor killing. Cancer Res., 60:788-792, 2000.
  266. Kagawa, S., Gu, J., Swisher, S.G., Ji, L., Roth, J.A., Lai, D., Stephens, L.C., and Fang, B. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res., 60:1157-1161, 2000.
  267. Nemunaitis, J., Swisher, S.G., Timmons, T., Connors, D., Mack, M., Doerksen, L., Savin, M., Weill, D., Shulkin, A., Wait, J., Ognoskie, N., Lawrence, D.D., Kemp, B.L., Fossella, F., Glisson, B.S., Hong, W.K., Khuri, F.R., Kurie, J.M., Lee, J.J., Lee, J.S., Nguyen, D.M., Nesbitt, J.C., Perez-Soler, R., Pisters, K.M.W., Putnam, J.B., Richli, W.R., Shin, D.M., Walsh, G.L., Merritt, J., and Roth, J.A. Adenovirus-mediated p53 gene transfer in squence with cisplatin to tumors of patients with non-small cell lung cancer. J. Clin. Oncol., 18:609-622, 2000.
  268. Putnam, J.B., Walsh, G.L., Swisher, S.G., Roth, J.A., Suell, D., Vaporciyan, A., Smythe, W.R., Merriman, K.W., and DeFord, L.L. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann. Thoracic Surg., 69:369-375, 2000.
  269. Kagawa, S., Pearson, S.A., Ji, L., Xu, K., Mcdonnell, T.J., Swisher, S.G., Roth, J.A., and Fang, B. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther., 7:75-79, 2000.
  270. Shao, J., Fujiwara, T., Kadowaki, Y., Fukazawa, T., Waku, T., Itoshima, T., Yamatsuji, T., Nishizaki, M., Roth, J.A., and Tanka, N. Overexpression of the wild-type p-53 gene inhibits NF-kB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene, 19:726-736, 2000.
  271. Kataoka M., Wiehle S., Spitz, F., Schumacher, G., Roth JA., and Cristiano RJ. Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells. Oncogene, 19:1589-1595, 2000.
  272. Swisher, S.G., and Roth, J.A. Gene therapy in lung cancer. Curr. Oncol. Rpts., 2:64-70
  273. Yen, N., Ioannides, C.G., Xu., K., Swisher, S.G., Lawrence, D.D., Kemp, B.L., El-Naggar, A.K., Cristiano, R.J., Fang, B., Glisson, B.S., Hong, W.K., Khuri, F.R., Kurie, J.M., Lee, J.J., Lee, J.S., Merritt, J.A., Mukhopadhyay, T., Nesbitt, J.C., Nguyen, D., Perez-Solar, R., Pisters, K.M.W., Putnam, J.B., Jr., Schrump, D.S., Shin, D.M., Walsh, G.L., and Roth, J.A. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wildtype p53 (Ad-p53). Cancer Gene Ther., 7:530-536, 2000
  274. Horio, Y., Hasegawa, Y., Sekido, Y., Roth, J.A., and Shimokata, K. Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells. Cancer Gene Ther., 7:537-544, 2000.
  275. Swisher, S. G., DeFord, L., Merriman, K. W., Walsh, G. L., Smythe, R., Vaporicyan, A., Ajani, J. A., Brown, T., Komaki, R., Roth, J. A., and Putnam, J. B. Effect of operative volume on morbidity, mortality and hospital use after esophagectomy for cancer. J.Thorac.Cardiovasc.Surg., 119:1126-1134, 2000.
  276. Owen-Schaub, L., Chan, H., Cusack, J.C., Roth, J.A., and Hill, L.L. Fas and Fas ligand interactions in malignant disease (review), Int. J. Oncol., 17:5-12, 2000.
  277. Komaki, R., Roth, J.A., Walsh, G., Putnam, J.B., Vaporciyan, A., Lee, J.S., Fossella, F.V., Chasen, M., Delclos, M.E., and Cox, J.D. Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at The University of Texas M. D. Anderson Cancer Center. Int. J. Oncol. Biol. Phys., 48:347-354, 2000
  278. Pearson, A.S., Spitz, F.R., Swisher, S.G., Kataoka, M., Sarkiss, M.G., Meyn, R.E, McDonnell, T.J., Cristiano, R.J., and Roth,J.A. Up-regulation of the proapoptotic mediators bax and bak following adenovirus-mediated p53 gene transfer in lung cancer cells. Clin. Cancer Res., 6:887-890, 2000.
  279. Schneider, P.M., Praeuer, H.W., Boehm, J., Manning, J., Metzger, R., Fink, U., Wegerer, S., Hoelscher, A.H. and Roth, J.A., Multiple molecular marker testing (p53, C-KI-RAS, C-ERBB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br. J. Cancer, 83:473-479, 2000.
  280. Itoshima, T., Fujiwara, T., Waku, T., Shao, J., Kataoka, M., Yarbrough, W.G., Liu, T.-J., Roth, J.A., Tanaka, N., and Kodama, M. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 downregulation. Clin. Cancer Res., 6:2851-2859, 2000.
  281. Sueoka, N., Lee, H., Walsh, G., Fang, B., Ji, L., Roth, J. A., LaPushin, R., Hong, W. K., Cohen, P., Kurie, J.. Insulin-like growth factor binding protein-6 inhibits the growth of retonic acid treatment. Oncogene, in press, 2000.
  282. Vaporciyan, A.A., Merriman, K.W., Ece, F., Roth, J.A., Smythe, W.R., Swisher, S.S., Walsh, G.L., Putnam, J.B., Jr. Impact of timing of smoking cessation on pulmonary morbidity after pneumonectomy. Ann. Thorac. Surg., in press, 2000.
  283. Pataer, A., Smythe, R., Yu, R., Fang, B., McDonnell, T., Roth, J.A., and Swisher,S.G. Adenoviral mediated bak gene transfer induces apoptosis in mesothelioma cell lines. J. Thoracic & Cardiovas. Surg., in press 2000.
  284. Saeki, T., Mhashilkar, A., Chada, S., Branch, C., Roth, J.A., and Ramesh,R. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer in vitro. Gene Ther., in press, 2000.
  285. Schnirer, I.I., Komaki, R., Yao, J.C., Swisher, S.G., Putnam, J.B., Jr., Pisters, P.W., Roth, J.A., and Ajani, J.A. A pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Amer. J. Clinic. Oncol., in press, 2000.
  286. Huober, J.B., Nakamura, S., Meyn, R., Roth, J.A., and Mukhopadhyay, T., Oral administration of an estrogen metabolite induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small cell lung cancer.Int. J. Rad. Oncol. Biol. Phys., in press, 2000.
  287. Gu, J., Kagawa, S., Takakura, M., Kyo, S., Inoue, M., Roth, J.A., and Fang, B. Tumor-specific transgene expression mediated by the hTERT promoter enables targeting of Bax gene apoptosis to cancer cells. Cancer Res. Adv. in Brief, in press, 2000.
  288. Kawabe, S., Roth, J.A., Meyn, R. Adenoviral-mediated p16INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner. Oncogene, in press, 2000.
  289. Kawabe, S., Munshi, A., Wilson, D.R., Roth, J.A., and Meyn, R.E. Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cells but not normal lung fibroblasts. Int. J. Radiat. Oncol. Biol. Phys., in press, 2000.

Back to Top